Clinical Trial: This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

Study Status: COMPLETED
Recruit Status: COMPLETED
Study Type: OBSERVATIONAL

Official Title: Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy

Brief Summary: This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.

Detailed Summary:
Sponsor: Pfizer

Current Primary Outcome: Describe and compare the rate of neurologic disease progression before and after initiation of tafamidis in patients with mixed-phenotype ATTRv-CM receiving tafamidis 80 mg or 61 mg daily in a real-world setting.

Original Primary Outcome: Describe and compare the rate of neurologic disease progression before and after initiation of tafamidis in patients with mixed-phenotype ATTRv-CM receiving tafamidis 80 mg or 61 mg daily in a real-world setting.

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Pfizer

Dates:
Date Received: November 17, 2021
Date Started: March 08, 2023
Date Completion: March 08, 2023
Last Updated: August 08, 2023
Last Verified: August 01, 2023